secwatch.observer — SEC 8-K summary
======================================

Issuer:     Enovis CORP (ENOV)
CIK:        0001420800
Form:       8-K
Filed at:   2023-02-23T23:59:59+00:00
Accession:  0001420800-23-000003
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Enovis Q4 net loss $0.71/sh, adj EPS $0.72; FY22 sales up 10% to $1.6B; guides FY23 adj EPS $2.15-2.30
--------------------------------------------------------------------------------

- Q4 net sales $409M (+2% YoY, +5% organic); Reconstructive segment organic growth 14%.
- Q4 adj EBITDA $75M (18.3% of sales), +290 bps YoY; full-year adj EBITDA margin 15.1% (+70 bps).
- FY22 net loss from continuing ops $38M ($0.25/diluted); adj EPS $2.27, up 15% YoY.
- FY23 guidance: organic revenue growth 5-6%, adj EBITDA $255-265M, adj EPS $2.15-2.30.
- Acquired Insight Medical Systems (ARVIS augmented reality) in 2022; acquisitions delivered double-digit organic growth.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1420800/000142080023000003/0001420800-23-000003-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1420800/000142080023000003/cfx-20230223.htm
  HTML page:      https://secwatch.observer/filing/0001420800-23-000003

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer